Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Novus Biologicals™ Nbs1 Overexpression Lysate
SDP

Catalog No. NBL113497 Shop All R&D Systems Products
Change view
Click to view available options
Quantity:
0.1 mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
NBL113497 0.1 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. NBL113497 Supplier Novus Biologicals™ Supplier No. NBL113497
Only null left
Add to Cart
Add to Cart
The Nbs1 Overexpression Lysate is derived from human. It has been validated for the following applications: Western Blot.

Specifications

Cell Line The lysate was created in HEK293T cells, using plasmid ID RC214682 and based on accession number NM_2485. The protein contains a C-terminal DDK tag.
For Use With (Application) Western Blot
Quantity 0.1 mg
Storage Buffer RIPA buffer
Purity Protein
Test Specificity Homo sapiens nibrin (NBN), mRNA.
Content And Storage -80°C. Avoid freeze-thaw cycles.
Research Category Breast Cancer, Cancer, Cell Cycle and Replication, Checkpoint signaling, Chromatin Research, DNA Double Strand Break Repair, DNA Repair, Homologous Recombination, Non homologous end joining, Tumor Suppressors
Synonym ATV, AT-V1, AT-V2, Cell cycle regulatory protein p95, FLJ10155, MGC87362, NBS, NBS1P95, nibrin, Nijmegen breakage syndrome 1 (nibrin), Nijmegen breakage syndrome protein 1, p95, p95 protein of the MRE11/RAD50 complex
Protein State Native

For Research Use Only

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.